Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2015, Vol. 9 Issue (3) : 384-387     DOI: 10.1007/s11684-015-0405-z
CASE REPORT |
Small cell carcinoma of the urinary bladder without gross hematuria: a case report
Wanqiu Huang1,2,Yang Luan1,Lu Jin1,Tao Wang1,Ruibao Chen1,Zheng Liu1,Zhiqiang Chen1,Ruzhu Lan1,*()
1. Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
2. Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
Download: PDF(535 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  

Small cell carcinoma of the urinary bladder (SCCB) is a rare and aggressive form of bladder cancer with poor prognosis. Hematuria is the main symptom of this malignancy, and most patients have a history of smoking. The disease incidence of malignant bladder tumors in China is approximately 0.74%. Early and accurate diagnosis of SCCB can ensure timely and appropriate treatment of this malignant disease. Oncologic surgery is the standard treatment; however, it may not be a curative approach. Chemotherapy and/or radiotherapy should be performed following surgical removal. This case report describes a patient with a single neoplasm diagnosed as SCCB that arose because of recurrence of bladder cancer after bladder tumor resection. In contrast to previously reported cases, this patient had no gross hematuria and no history of smoking.

Keywords carcinoma      small cell      urinary bladder neoplasms      diagnosis     
Corresponding Authors: Ruzhu Lan   
Just Accepted Date: 08 July 2015   Online First Date: 11 August 2015    Issue Date: 26 August 2015
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-015-0405-z     OR     http://academic.hep.com.cn/fmd/EN/Y2015/V9/I3/384
Fig.1  (A) CT scan showing a papillomatous mass arising from the back wall of the bladder. (B) A portion of the bladder tissue was resected, which contained an exogenous mass (3 cm × 2 cm in size) adhering to the adjacent peritoneum.
Fig.2  (A) H&E stain of the tumor. Immunohistochemical staining revealed that the tumor cells were positive for EMA (B), CD56 (C), CK-PAN (D), and SYN (E), but negative for CK20 (F), CD45 (G), and CgA (H) (200×).
1 Cheng L, Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Lin H, Kuzel TM, Papavero V, Tretiakova M, Nigro K, Koch MO, Eble JN. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer 2004; 101(5): 957–962
doi: 10.1002/cncr.20456 pmid: 15329903
2 Trias I, Algaba F, Condom E, Espa?ol I, Seguí J, Orsola I, Villavicencio H, García Del Muro X. Small cell carcinoma of the urinary bladder. Presentation of 23 cases and review of 134 published cases. Eur Urol 2001; 39(1): 85–90
doi: 10.1159/000052417 pmid: 11173944
3 Cramer SF, Aikawa M, Cebelin M. Neurosecretory granules in small cell invasive carcinoma of the urinary bladder. Cancer 1981; 47(4): 724–730
doi: 10.1002/1097-0142(19810215)47:4<724::AID-CNCR2820470417>3.0.CO;2-2 pmid: 6261916
4 Blomjous CE, Vos W, De Voogt HJ, Van der Valk P, Meijer CJ. Small cell carcinoma of the urinary bladder. A clinicopathologic, morphometric, immunohistochemical, and ultrastructural study of 18 cases. Cancer 1989; 64(6): 1347–1357
doi: 10.1002/1097-0142(19890915)64:6<1347::AID-CNCR2820640629>3.0.CO;2-Q pmid: 2548704
5 Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer 2005; 103(6): 1172–1178
doi: 10.1002/cncr.20903 pmid: 15700264
6 Hou CP, Lin YH, Chen CL, Chang PL, Tsui KH. Clinical outcome of primary small cell carcinoma of the urinary bladder. Onco Targets Ther 2013; 6: 1179–1185
pmid: 24009428
7 Sved P, Gomez P, Manoharan M, Civantos F, Soloway MS. Small cell carcinoma of the bladder. BJU Int 2004; 94(1): 12–17
doi: 10.1111/j.1464-410X.2003.04893.x pmid: 15217423
8 Ismaili N, Elkarak F, Heudel PE, Flechon A, Droz JP. Small cell cancer of the bladder: The Leon-Berard cancer centre experience. Indian J Urol 2008; 24(4): 494–497
doi: 10.4103/0970-1591.44255 pmid: 19468504
9 Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, Grossman HB, Swanson DA, Millikan RE. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol 2004; 172(2): 481–484
doi: 10.1097/01.ju.0000132413.85866.fc pmid: 15247709
10 Lohrisch C, Murray N, Pickles T, Sullivan L. Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation. Cancer 1999; 86(11): 2346–2352
doi: 10.1002/(SICI)1097-0142(19991201)86:11<2346::AID-CNCR24>3.0.CO;2-5 pmid: 10590377
11 Reyes CV, Soneru I. Small cell carcinoma of the urinary bladder with hypercalcemia. Cancer 1985; 56(10): 2530–2533
doi: 10.1002/1097-0142(19851115)56:10<2530::AID-CNCR2820561035>3.0.CO;2-4 pmid: 2994881
12 Gon S, Majumdar B, Dey RK, Mitra SK. Pure primary small cell carcinoma of urinary bladder: a rare diagnostic entity. Urol Ann 2013; 5(3): 209–211
doi: 10.4103/0974-7796.115751 pmid: 24049389
13 Epstein JI, Amin MB, Reuter VE. Bladder biopsy interpretation. MA: Lippincott Williams and Wilkins 2004: 126–128
14 Jones TD, Kernek KM, Yang XJ, Lopez-Beltran A, MacLennan GT, Eble JN, Lin H, Pan CX, Tretiakova M, Baldridge LA, Cheng L. Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases. Hum Pathol 2005; 36(7): 718–723
doi: 10.1016/j.humpath.2005.04.007 pmid: 16084939
15 Soriano P, Navarro S, Gil M, Llombart-Bosch A. Small-cell carcinoma of the urinary bladder. A clinico-pathological study of ten cases. Virchows Arch 2004; 445(3): 292–297
doi: 10.1007/s00428-004-1041-1 pmid: 15248064
16 Karpman E, Goldberg Z, Saffarian A, Gandour-Edwards R, Ellison LM, deVere White RW. Analysis of treatment for small cell cancer of the bladder and report of three cases. Urology 2004; 64(3): 494–498
doi: 10.1016/j.urology.2004.04.038 pmid: 15351578
17 Iczkowski KA, Shanks JH, Bostwick DG. Loss of CD44 variant 6 expression differentiates small cell carcinoma of urinary bladder from urothelial (transitional cell) carcinoma. Histopathology 1998; 32(4): 322–327
doi: 10.1046/j.1365-2559.1998.00398.x pmid: 9602328
18 Alijo Serrano F, Sánchez-Mora N, Angel Arranz J, Hernández C, Alvarez-Fernández E. Large cell and small cell neuroendocrine bladder carcinoma: immunohistochemical and outcome study in a single institution. Am J Clin Pathol 2007; 128(5): 733–739
doi: 10.1309/HTREM6QYQDYGNWYA
19 Church DN, Bahl A. Clinical review—<?Pub Caret?>small cell carcinoma of the bladder. Cancer Treat Rev 2006; 32(8): 588–593
doi: 10.1016/j.ctrv.2006.07.013 pmid: 17008012
20 Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur Urol 2003; 44(6): 672–681
doi: 10.1016/S0302-2838(03)00416-0 pmid: 14644119
21 Abrahams NA, Moran C, Reyes AO, Siefker-Radtke A, Ayala AG. Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology 2005; 46(1): 57–63
doi: 10.1111/j.1365-2559.2004.01980.x pmid: 15656887
[1] Xinsen Xu,Yanyan Zhou,Runchen Miao,Wei Chen,Kai Qu,Qing Pang,Chang Liu. Transcriptional modules related to hepatocellular carcinoma survival: coexpression network analysis[J]. Front. Med., 2016, 10(2): 183-190.
[2] Shuyang Sun,Zhiyuan Zhang. Patient-derived xenograft platform of OSCC: a renewable human bio-bank for preclinical cancer research and a new co-clinical model for treatment optimization[J]. Front. Med., 2016, 10(1): 104-110.
[3] Zhi Xu,Chunxiang Cao,Haiyan Xia,Shujing Shi,Lingzhi Hong,Xiaowei Wei,Dongying Gu,Jianmin Bian,Zijun Liu,Wenbin Huang,Yixin Zhang,Song He,Nikki Pui-Yue Lee,Jinfei Chen. Protein phosphatase magnesium-dependent 1δ is a novel tumor marker and target in hepatocellular carcinoma[J]. Front. Med., 2016, 10(1): 52-60.
[4] Jing Zhang,Shan Gao,Zhongping Duan,Ke-Qin Hu. Overview on acute-on-chronic liver failure[J]. Front. Med., 2016, 10(1): 1-17.
[5] Lijuan Hu,Zhirui Lin,Yanheng Wu,Juqin Dong,Bo Zhao,Yanbing Cheng,Peiyu Huang,Lihua Xu,Tianliang Xia,Dan Xiong,Hongbo Wang,Manzhi Li,Ling Guo,Elliott Kieff,Yixin Zeng,Qian Zhong,Musheng Zeng. Comprehensive profiling of EBV gene expression in nasopharyngeal carcinoma through paired-end transcriptome sequencing[J]. Front. Med., 2016, 10(1): 61-75.
[6] Jiangbo Du,Wenjie Xue,Yong Ji,Xun Zhu,Yayun Gu,Meng Zhu,Cheng Wang,Yong Gao,Juncheng Dai,Hongxia Ma,Yue Jiang,Jiaping Chen,Zhibin Hu,Guangfu Jin,Hongbing Shen. U-shaped association between telomere length and esophageal squamous cell carcinoma risk: a case-control study in Chinese population[J]. Front. Med., 2015, 9(4): 478-486.
[7] Yi Cao. Environmental pollution and DNA methylation: carcinogenesis, clinical significance, and practical applications[J]. Front. Med., 2015, 9(3): 261-274.
[8] Felice Ho-Ching Tsang,Sandy Leung-Kuen Au,Lai Wei,Dorothy Ngo-Yin Fan,Joyce Man-Fong Lee,Carmen Chak-Lui Wong,Irene Oi-Lin Ng,Chun-Ming Wong. MicroRNA-142-3p and microRNA-142-5p are downregulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility[J]. Front. Med., 2015, 9(3): 331-343.
[9] Lingqiang Zhang,Runchen Miao,Xiude Zhang,Wei Chen,Yanyan Zhou,Ruitao Wang,Ruiyao Zhang,Qing Pang,Xinsen Xu,Chang Liu. Exploring the diagnosis markers for gallbladder cancer based on clinical data[J]. Front. Med., 2015, 9(3): 350-355.
[10] Farhad Sahebjam,John M. Vierling. Autoimmune hepatitis[J]. Front. Med., 2015, 9(2): 187-219.
[11] Guanghua Rong,Wenlin Bai,Zheng Dong,Chunping Wang,Yinying Lu,Zhen Zeng,Jianhui Qu,Min Lou,Hong Wang,Xudong Gao,Xiujuan Chang,Linjing An,Yan Chen,Yongping Yang. Cryotherapy for cirrhosis-based hepatocellular carcinoma: a single center experience from 1595 treated cases[J]. Front. Med., 2015, 9(1): 63-71.
[12] Xiaolong Wei,Chunfa Chen,Didi Xi,Jinwen Bai,Wenhe Huang,Luoxiang Rong,Mingyao Wu,Guojun Zhang. A case of primary neuroendocrine breast carcinoma that responded to neo-adjuvant chemotherapy[J]. Front. Med., 2015, 9(1): 112-116.
[13] Marielle Reataza,David K. Imagawa. Advances in managing hepatocellular carcinoma[J]. Front. Med., 2014, 8(2): 175-189.
[14] Kai Qu,Ting Lin,Zhixin Wang,Sinan Liu,Hulin Chang,Xinsen Xu,Fandi Meng,Lei Zhou,Jichao Wei,Minghui Tai,Yafeng Dong,Chang Liu. Reactive oxygen species generation is essential for cisplatin-induced accelerated senescence in hepatocellular carcinoma[J]. Front. Med., 2014, 8(2): 227-235.
[15] Du Yan, Han Xue, Pu Rui, Xie Jiaxin, Zhang Yuwei, Cao Guangwen. Association of miRNA-122-binding site polymorphism at the interleukin-1 α gene and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk[J]. Front. Med., 2014, 8(2): 217-226.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed